GlassScriptPhysician profile
Sana Najib
NPI 1538676473
$8,459.88
in general payments reported to CMS, 2019-2025
59 companies · $3,017 in 2025
The $3,017 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.05 · 2021: $17.22 · 2022: $46.41 · 2023: $1,315 · 2024: $4,050 · 2025: $3,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,823 · Education: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,822.64 |
| Education | $559.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $592.96 | 2022-2025 | Opdivo, Reblozyl, Opdualag |
| Gilead Sciences, INC. | $562.35 | 2023-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $404.28 | 2023-2025 | Enhertu, Lynparza, Tagrisso |
| Regeneron Healthcare Solutions, INC. | $370.89 | 2024-2025 | Libtayo |
| Daiichi Sankyo INC. | $369.44 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $336.30 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $315.59 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $293.86 | 2023-2025 | |
| Genzyme Corporation | $286.89 | 2021-2025 | |
| Incyte Corporation | $275.95 | 2023-2025 | Jakafi |
| Eisai INC. | $273.69 | 2023-2025 | |
| Beigene USA, INC. | $257.35 | 2023-2025 | Brukinsa, Tevimbra |
| Janssen Biotech, INC. | $255.43 | 2023-2025 | Erleada, Rybrevant, Tecvayli |
| Celgene Corporation | $231.15 | 2023-2025 | Reblozyl, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $207.25 | 2022-2025 | Ninlaro, Fruzaqla, Iclusig |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $200.07 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Beone Medicines USA, INC. | $197.98 | 2025 | Brukinsa, Tevimbra |
| Genentech USA, INC. | $193.94 | 2023-2025 | Venclexta, Tecentriq, Alecensa |
| Array Biopharma INC | $169.30 | 2020-2025 | Mektovi, Lorbrena, Braftovi |
| Seagen INC. | $151.01 | 2023-2025 | Tukysa |
| Abbvie INC. | $148.19 | 2024-2025 | |
| Puma Biotechnology, INC. | $144.40 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $144.39 | 2023-2025 | |
| Glaxosmithkline, LLC. | $141.75 | 2025 | Ojjaara, Jemperli, Zejula |
| Exelixis INC. | $129.73 | 2023-2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $123.18 | 2024-2025 | |
| Cumberland Pharmaceuticals, INC. | $108.02 | 2024-2025 | Sancuso |
| Alexion Pharmaceuticals, INC. | $105.97 | 2023-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $98.35 | 2024-2025 | |
| Amgen INC. | $93.89 | 2023 | Xgeva, Nplate, Vectibix |
| Taiho Oncology, INC. | $92.47 | 2023-2024 | |
| Mirati Therapeutics, INC. | $89.23 | 2023-2024 | Krazati |
| Foundation Medicine, INC. | $88.26 | 2023 | |
| Tempus Ai, INC | $87.43 | 2024 | |
| Pharmaessentia USA Corporation | $76.52 | 2023-2024 | Besremi |
| Sobi, INC | $65.96 | 2022-2024 | |
| Lilly USA, LLC | $65.82 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Adaptive Biotechnologies Corporation | $65.79 | 2024-2025 | Clonoseq |
| Pharmacosmos Therapeutics INC. | $58.88 | 2023-2024 | Monoferric |
| Genmab U.S., INC. | $55.88 | 2024-2025 | Tivdak, Epkinly |
| Blueprint Medicines Corporation | $54.85 | 2024 | Ayvakit |
| Coherus Oncology, INC. | $50.81 | 2024-2025 | Loqtorzi |
| Invivyd INC | $48.86 | 2025 | Pemgarda |
| Geron Corporation | $44.07 | 2025 | Rytelo |
| Apellis Pharmaceuticals, INC. | $37.76 | 2024 | Empaveli |
| Emd Serono, INC. | $35.18 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $32.10 | 2024 | Vivimusta |
| Springworks Therapeutics, INC. | $32.01 | 2024 | Ogsiveo |
| Stemline Therapeutics INC. | $29.50 | 2024 | Orserdu |
| Karyopharm Therapeutics INC. | $29.31 | 2024 | Xpovio |
| Jazz Pharmaceuticals INC. | $19.39 | 2023 | |
| Dendreon Pharmaceuticals LLC | $16.88 | 2025 | Provenge |
| Astellas Pharma US INC | $16.84 | 2025 | Vyloy |
| Kite Pharma, INC. | $16.50 | 2025 | Yescarta |
| Morphosys, US INC. | $15.76 | 2023 | Monjuvi |
| Biocon Biologics INC | $15.44 | 2024 | Ogivri |
| Deciphera Pharmaceuticals INC. | $14.17 | 2024 | Qinlock |
| Tersera Therapeutics LLC | $13.79 | 2025 | Xermelo |
| Iovance Biotherapeutics, INC. | $6.87 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sana Najib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.